ASLAN PHARMACEU/ADR (NASDAQ:ASLN) Given a $9.00 Price Target by HC Wainwright Analysts

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) has been given a $9.00 target price by HC Wainwright in a research report issued to clients and investors on Wednesday, June 5th, TipRanks reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 193.16% from the company’s previous close.

Separately, Zacks Investment Research downgraded shares of ASLAN PHARMACEU/ADR from a “buy” rating to a “hold” rating in a research report on Monday, May 27th.

Shares of ASLN stock remained flat at $$3.07 during trading hours on Wednesday. 9,943 shares of the stock were exchanged, compared to its average volume of 20,115. ASLAN PHARMACEU/ADR has a twelve month low of $2.51 and a twelve month high of $9.00. The firm has a fifty day moving average of $3.46. The company has a quick ratio of 5.19, a current ratio of 3.64 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $98.33 million and a price-to-earnings ratio of -2.19.

ASLAN PHARMACEU/ADR (NASDAQ:ASLN) last released its quarterly earnings results on Monday, April 29th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.07. The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $2.70 million. Sell-side analysts expect that ASLAN PHARMACEU/ADR will post -0.73 earnings per share for the current year.


ASLAN Pharmaceuticals Limited, a clinical-stage oncology-focused biopharmaceutical company, engages in the development of drugs for prevalent cancers. It targets diseases that are prevalent in Asia, and orphan indications in the United States and Europe. The company's lead program, varlitinib, is a reversible small molecule pan-human epidermal growth factor receptor, or pan-HER, inhibitor that targets the human epidermal growth factor receptors HER1, HER2, and HER4.

See Also: Compound Annual Growth Rate (CAGR)

Receive News & Ratings for ASLAN PHARMACEU/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN PHARMACEU/ADR and related companies with's FREE daily email newsletter.